Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community

被引:79
作者
Vernaz, Nathalie [1 ,2 ]
Huttner, Benedikt [2 ,3 ]
Muscionico, Daniel [4 ]
Salomon, Jean-Luc [4 ]
Bonnabry, Pascal [1 ,2 ]
Maria Lopez-Lozano, Jose [5 ]
Beyaert, Arielle [6 ]
Schrenzel, Jacques [2 ,7 ]
Harbarth, Stephan [2 ,3 ]
机构
[1] Univ Hosp Geneva, Dept Pharm, Geneva, Switzerland
[2] Univ Geneva, Sch Med, CH-1211 Geneva, Switzerland
[3] Univ Hosp Geneva, Infect Control Program, Geneva, Switzerland
[4] Invoice Off, OFAC, Geneva, Switzerland
[5] Hosp Vega Baja, Invest Unit, Alicante, Spain
[6] Univ Murcia, Dept Quantitat Methods Econ & Business, Murcia, Spain
[7] Univ Hosp Geneva, Clin Microbiol Lab, Geneva, Switzerland
关键词
antibiotic resistance; E; coli; fluoroquinolone resistance; extended-spectrum beta-lactamase-producing bacteria; transfer function model; health policy making; time-series analysis; LACTAMASE-PRODUCING ENTEROBACTERIACEAE; RISK-FACTORS; FLUOROQUINOLONE RESISTANCE; SULFONAMIDE RESISTANCE; STAPHYLOCOCCUS-AUREUS; ANTIMICROBIAL USE; CONSUMPTION; TIME; EMERGENCE; COLONIZATION;
D O I
10.1093/jac/dkq525
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To determine the temporal relationship between antibiotic use and incidence of antibiotic-resistant Escherichia coli in both the inpatient and outpatient setting of a large urban area. Methods: A retrospective observational time-series analysis was performed to evaluate the incidence of non-duplicate clinical isolates of E. coli resistant to ciprofloxacin, trimethoprim/sulfamethoxazole and cefepime from January 2000 through December 2007, combined with a transfer function model of aggregated data on antibiotic use in both settings obtained from the hospital's pharmacy and outpatient billing offices. Results: Ciprofloxacin resistance increased from 6.0% (2000) to 15.4% (2007; P < 0.0001) and cefepime resistance from 0.9% (2002) to 3.2% (2007; P = 0.01). Trimethoprim/sulfamethoxazole resistance remained stable (23.7%-25.8%). Total antibiotic use increased in both settings, while fluoroquinolone use increased significantly only among outpatients. A temporal effect between fluoroquinolone resistance in community E. coli isolates and outpatient use of ciprofloxacin (immediate effect and time lag 1 month) and moxifloxacin (time lag 4 months) was observed, explaining 51% of the variance over time. The incidence of cefepime resistance in E. coli was correlated with ciprofloxacin use in the inpatient (lag 1 month) and outpatient (lag 4 months) settings and with the use of ceftriaxone (lag 0 month), piperacillin/tazobactam (3 months) and cefepime (3 months) in the hospital (R-2 = 51%). Conclusions: These results support efforts to reduce prescribing of fluoroquinolones for control of resistant E. coli including extended-spectrum beta-lactamase producers and show the added value of time-series analysis to better understand the interaction between community and hospital antibiotic prescribing and its spill-over effect on antibiotic resistance.
引用
收藏
页码:928 / 935
页数:8
相关论文
共 42 条
  • [31] The Prevalence of Fluoroquinolone Resistance Mechanisms in Colonizing Escherichia coli Isolates Recovered from Hospitalized Patients
    Lautenbach, Ebbing
    Metlay, Joshua P.
    Mao, Xiangqun
    Han, Xiaoyan
    Fishman, Neil O.
    Bilker, Warren B.
    Tolomeo, Pam
    Wheeler, Mary
    Nachamkin, Irving
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 51 (03) : 280 - 285
  • [32] Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use:: a time series analysis
    López-Lozano, JM
    Monnet, DL
    Yagüe, A
    Burgos, A
    Gonzalo, N
    Campillos, P
    Saez, M
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 14 (01) : 21 - 31
  • [33] Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals
    MacDougall, C
    Powell, JP
    Johnson, CK
    Edmond, MB
    Polk, RE
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (04) : 435 - 440
  • [34] Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome
    Ortega, M.
    Marco, F.
    Soriano, A.
    Almela, M.
    Martinez, J. A.
    Munoz, A.
    Mensa, J.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (03) : 568 - 574
  • [35] Diversity of antimicrobial use and resistance in 42 hospitals in the United States
    Pakyz, Amy
    Powell, J. Patrick
    Harpe, Spencer E.
    Johnson, Chris
    Edmond, Michael
    Polk, Ron E.
    [J]. PHARMACOTHERAPY, 2008, 28 (07): : 906 - 912
  • [36] Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4
    Peirano, Gisele
    Pitout, Johann D. D.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (04) : 316 - 321
  • [37] Measurement of adult antibacterial drug use in 130 US hospitals: Comparison of defined daily dose and days of therapy
    Polk, Ronald E.
    Fox, Christina
    Mahoney, Anne
    Letcavage, Jim
    MacDougall, Conan
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (05) : 664 - 670
  • [38] Significant Reduction of Antibiotic Use in the Community after a Nationwide Campaign in France, 2002-2007
    Sabuncu, Elifsu
    David, Julie
    Bernede-Bauduin, Claire
    Pepin, Sophie
    Leroy, Michel
    Boelle, Pierre-Yves
    Watier, Laurence
    Guillemot, Didier
    [J]. PLOS MEDICINE, 2009, 6 (06)
  • [39] Stone SP, 2007, J ANTIMICROB CHEMOTH, V59, P833, DOI [10.1093/jac/dkm055, 10.1016/S1473-3099(07)70082-8]
  • [40] Hospital consumption of antibiotics in 15 European countries: results of the ESAC retrospective data collection (1997-2002)
    VanderStichele, R. H.
    Elseviers, M. M.
    Ferech, M.
    Blot, S.
    Goossens, H.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (01) : 159 - 167